Bellevue Life Sciences Acquisition Corp. (BLACR)
| Previous close | 0.1100 |
| Open | 0.1400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.1400 - 0.1503 |
| 52-week range | 0.1400 - 0.1503 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting
As previously announced, on May 10, 2024, Bellevue Life Sciences Acquisitions Corp. (Nasdaq: BLAC) ("BLAC") convened a special meeting of stockholders (the "Special Meeting"), adjourned the Special Meeting without any business being conducted, and announced that the Special Meeting will be reconvened at 9:00 a.m. Pacific time on Tuesday, May 14, 2024, at 925 Fourth Avenue, Suite 2900, Seattle, WA 98104. At the reconvened Special Meeting, stockholders will consider and vote upon the matters descr
- PR Newswire
/C O R R E C T I O N -- OSR Holdings/
OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical development resources and launch a strategic collaboration between the two companies. Through the MOU, the two companies will explore various ways to collaborate to create synergies between current platform technologies and new drug candidates.
